6/10/2013 8:49:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
The FDA says Hospira’s India facility is still rife with significant violations of good manufacturing practice regulations. Hospira (NYSE:HSP) heard from the FDA's inspection office this week with another warning that the infusion device company's India facility still contains significant violations of good manufacturing practice regulations. The FDA originally inspected the Industrial Park, Irungattukottai, Sriperumburdur, India facility in October 2012 and found serious problem with workplace sanitation, product sterility and processing violations that meant the products coming out of that plant were considered adulterated under law.
Help employers find you! Check out all the jobs and post your resume.
comments powered by